- Home
- XFOR vs ZVRA Comparison
XFOR vs ZVRA Comparison
Compare XFOR & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XFOR | ZVRA |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | 143 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.5M | 472.9M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | XFOR | ZVRA |
|---|---|---|
| Price | $4.41 | $9.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $25.20 | $23.00 |
| AVG Volume (30 Days) | 495.0K | ★ 1.1M |
| Earning Date | 03-17-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 1.35 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | N/A | $37.27 |
| Revenue Next Year | $80.31 | $53.42 |
| P/E Ratio | ★ N/A | $6.90 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $0.17 | $6.19 |
| 52 Week High | $6.63 | $13.16 |
Technical Indicators
Market Signals| Indicator | XFOR | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 58.40 | 51.71 |
| Support Level | $3.01 | $8.33 |
| Resistance Level | $4.83 | $9.83 |
| Average True Range (ATR) | 0.36 | 0.43 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 88.27 | 34.00 |
Price Performance
Historical ComparisonAbout XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.